Compare ALEMBIC with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs JUBILANT PHARMOVA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC JUBILANT PHARMOVA ALEMBIC/
JUBILANT PHARMOVA
 
P/E (TTM) x 59.7 13.4 445.6% View Chart
P/BV x 5.1 2.5 205.7% View Chart
Dividend Yield % 0.2 0.6 33.3%  

Financials

 ALEMBIC   JUBILANT PHARMOVA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
JUBILANT PHARMOVA
Mar-19
ALEMBIC/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs72898 8.0%   
Low Rs34618 5.5%   
Sales per share (Unadj.) Rs4.7572.0 0.8%  
Earnings per share (Unadj.) Rs6.136.2 16.8%  
Cash flow per share (Unadj.) Rs6.259.5 10.5%  
Dividends per share (Unadj.) Rs0.204.50 4.4%  
Dividend yield (eoy) %0.40.6 63.6%  
Book value per share (Unadj.) Rs40.7301.9 13.5%  
Shares outstanding (eoy) m267.03159.28 167.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.31.3 850.3%   
Avg P/E ratio x8.720.9 41.5%  
P/CF ratio (eoy) x8.512.7 66.6%  
Price / Book Value ratio x1.32.5 51.9%  
Dividend payout %3.312.4 26.4%   
Avg Mkt Cap Rs m14,139120,694 11.7%   
No. of employees `000NA2.4 0.0%   
Total wages/salary Rs m20719,260 1.1%   
Avg. sales/employee Rs ThNM38,120.6-  
Avg. wages/employee Rs ThNM8,058.4-  
Avg. net profit/employee Rs ThNM2,414.3-  
INCOME DATA
Net Sales Rs m1,25591,108 1.4%  
Other income Rs m370357 103.6%   
Total revenues Rs m1,62591,466 1.8%   
Gross profit Rs m11117,390 0.6%  
Depreciation Rs m383,709 1.0%   
Interest Rs m22,198 0.1%   
Profit before tax Rs m44211,840 3.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m243,268 0.7%   
Profit after tax Rs m1,6305,770 28.2%  
Gross profit margin %8.919.1 46.4%  
Effective tax rate %5.427.6 19.6%   
Net profit margin %129.86.3 2,050.3%  
BALANCE SHEET DATA
Current assets Rs m1,86745,848 4.1%   
Current liabilities Rs m59120,897 2.8%   
Net working cap to sales %101.627.4 371.2%  
Current ratio x3.22.2 143.9%  
Inventory Days Days9457 166.0%  
Debtors Days Days7451 144.4%  
Net fixed assets Rs m1,79165,498 2.7%   
Share capital Rs m534159 335.3%   
"Free" reserves Rs m10,32447,930 21.5%   
Net worth Rs m10,85848,089 22.6%   
Long term debt Rs m4142,429 0.1%   
Total assets Rs m11,591114,685 10.1%  
Interest coverage x260.96.4 4,084.8%   
Debt to equity ratio x00.9 0.4%  
Sales to assets ratio x0.10.8 13.6%   
Return on assets %14.16.9 202.6%  
Return on equity %15.012.0 125.1%  
Return on capital %15.212.4 122.4%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1912,422 0.2%   
Fx outflow Rs m26417,227 1.5%   
Net fx Rs m-244-4,805 5.1%   
CASH FLOW
From Operations Rs m23611,215 2.1%  
From Investments Rs m-224-10,118 2.2%  
From Financial Activity Rs m-276,574 -0.4%  
Net Cashflow Rs m-157,612 -0.2%  

Share Holding

Indian Promoters % 64.0 45.6 140.4%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.2 8.7 2.3%  
FIIs % 9.7 21.2 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.1 123.7%  
Shareholders   54,701 23,815 229.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Mar 8, 2021 03:32 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS